.Attribute Medication, Released online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Viewpoint calls for inclusion of clients with MASLD and dimension of liver end results in cardio-- renal-- metabolic tests, when data advise mechanistically possible advantages as well as scientific safety and security-- and also details factors for trial concept and regulative commendation.